Hospitals

Medtronic deep-brain stimulation therapy OK’d for obsessive compulsive disorder

The U.S. Food and Drug Administration approved a Medtronic deep brain stimulation treatment to treat obsessive compulsive disorder – the first deep brain stimulation treatment to be used for psychiatric problems.

MINNEAPOLIS, Minnesota — The U.S. Food and Drug Administration approved a Medtronic deep brain stimulation treatment to treat obsessive compulsive disorder – the first deep brain stimulation treatment to be used for psychiatric problems, according to a press release.

The FDA granted the medical device giant’s Reclaim Deep Brain Stimulation Therapy a humanitarian device exemption. It should be available by the middle of this year.

Medtronic estimates fewer than 4,000 patients a year would use its treatment for obsessive compulsive disorder – a requirement to receive the label as a humanitarian use device.

In addition, Medtronic said it has initiated a national clinical trial of deep brain stimulation for treatment-resistant depression. Among the hospital systems involved is the Cleveland Clinic, which was the first to enroll a patient in the trial.

Two of the Clinic’s top deep brain stimulations physicians – Dr. Ali Rezai and Dr. Donald Malone – help lead the trials and are paid consultants for Medtronic. “The clinical trial of DBS in treatment-resistant depression is an important step in understanding this therapeutic approach for patients with severe depression,” Rezai said.